Residential School on Medicinal Chemistry and Biology in Drug Discovery

 

Drew University’s Residential School on Medicinal Chemistry and Biology in Drug Discovery (ResMed)

IMPORTANT INFORMATION

Given the uncertainty surrounding the COVID-19 pandemic, the ResMed staff and Drew University have decided to cancel this year’s ResMed course scheduled for June 7-12, 2020 at the Hyatt Regency in Morristown, NJ. A separate e-mail will be sent to those who have registered regarding the option to receive a refund or roll over registration to next year’s course.

ResMed 2021 is tentatively scheduled for June 6-11, 2021 at the Hyatt Regency in Morristown, NJ. Registration for the course will begin November 1, 2020; check our website in October for any updates on next year’s course. Given the popularity of the course and this year’s unfortunate cancellation, we anticipate registration to be brisk as we are limited to a 200-person class size.
If you have any questions, do not hesitate to reach out to us: resmed@drew.edu.

Keynote 2020

Michael J. Sofia, Ph.D. is Co-founder and Chief Scientific Officer of Arbutus Biopharma, Inc. a company focused on the discovery and development of therapies to cure hepatitis B. Previously Mike was Sr. Vice President of Chemistry at Pharmasset, Inc. Mike has also held research and research management positions at Gilead Sciences, Bristol-Myers Squibb, Transcell Technologies and Eli Lilly and Company…

Drew University’s Residential School on Medicinal Chemistry and Biology in Drug Discovery (ResMed) course will be held June 7-12, 2020 at the Hyatt Regency-Morristown.

ResMed is a graduate level course designed for chemists and biologists  interested in broadening their understanding of the fundamental principles of drug discovery research and pre-clinical development. Scientists from related disciplines would also gain a clearer appreciation for the processes and methods important to drug discovery through clinical development.

Course attendees staying at the hotel will enjoy beautifully appointed, single-occupancy rooms and a breakfast buffet.

 

Case History Spotlight

ResMed provides case histories for drugs that have successfully made it from the “bench to the bedside”: BELSOMRA® (suvorexant, insomnia), Erivedge® (vismodegib, basal cell carcinoma), PROMACTA® (eltrombopag, thrombocytopenia), and Trikafta™ (elexacaftor/ivacaftor/tezacaftor), a new combination therapy for cystic fibrosis recently approved by the FDA.